Clinical trial
Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia.
NCT04031742 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia.
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 29, 2019
- Completion date
- December 30, 2021
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.